Notably, a meta-analysis showing a higher CSF NfL in RRMS over progressive MS participants (with a small, albeit significant effect size) utilized the same ELISA employed in 12 of the 13 ELISA studies in our review (67). The gene discussed is NEFL; the disease is myeloid sarcoma.